Connection | Profiles RNS

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

Usmani, Saad

One or more keywords matched the following items that are connected to Usmani, Saad

Item Type	Name
Concept	Tumor Suppressor Protein p53
Concept	Genes, Tumor Suppressor
Concept	Hematologic Neoplasms
Concept	Biomarkers, Tumor
Concept	Neoplasms, Second Primary
Concept	Bone Neoplasms
Concept	Tumor Cells, Cultured
Concept	Neoplasm Recurrence, Local
Concept	Genes, Neoplasm
Concept	Liver Neoplasms
Concept	Soft Tissue Neoplasms
Concept	Cancer Care Facilities
Concept	Central Nervous System Neoplasms
Concept	Neoplasms, Plasma Cell
Concept	Neoplasm Proteins
Concept	Neoplasm Staging
Concept	Drug Resistance, Neoplasm
Concept	Neoplasm Transplantation
Concept	Breast Neoplasms
Concept	Neoplasms
Concept	Skin Neoplasms
Concept	Neoplasm, Residual
Concept	Cell Line, Tumor
Concept	Tumor Suppressor Proteins
Academic Article	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.
Academic Article	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
Academic Article	Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Academic Article	Multiple myeloma: is it time for biomarker-driven therapy?
Academic Article	Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.
Academic Article	Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.
Academic Article	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups.
Academic Article	Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project.
Academic Article	CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
Academic Article	Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma.
Academic Article	Transient bacteremia induced by dental cleaning is not associated with infection of central venous catheters in patients with cancer.
Academic Article	Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.
Academic Article	Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.
Academic Article	Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
Academic Article	Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma.
Academic Article	A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
Academic Article	Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Academic Article	Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma.
Academic Article	Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.
Academic Article	Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Academic Article	Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.
Academic Article	Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1.
Academic Article	NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.
Academic Article	Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3.
Academic Article	Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Academic Article	Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.
Academic Article	The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.
Academic Article	Molecular chaperone gp96 is a novel therapeutic target of multiple myeloma.
Academic Article	Patterns of central nervous system involvement in relapsed and refractory multiple myeloma.
Academic Article	Cutaneous manifestations of multiple myeloma and other plasma cell proliferative disorders.
Academic Article	Maintenance lenalidomide after transplantation: How much is enough?
Academic Article	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
Academic Article	The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.
Academic Article	Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.
Academic Article	Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison.
Academic Article	Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma.
Academic Article	A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Academic Article	INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma.
Academic Article	Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses.
Academic Article	Chemotherapy-induced thymus hyperplasia can mimic tumor recurrence.
Academic Article	Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma.
Academic Article	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.
Academic Article	Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.
Academic Article	BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.
Academic Article	17 AAG for HSP90 inhibition in cancer--from bench to bedside.
Academic Article	Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.
Academic Article	Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
Academic Article	Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.
Academic Article	Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.
Academic Article	Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
Academic Article	Extramedullary Disease in Multiple Myeloma.
Academic Article	Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
Academic Article	Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma.
Academic Article	Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
Academic Article	An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma.
Academic Article	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
Academic Article	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.
Academic Article	Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results.
Academic Article	International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).
Academic Article	Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma.
Academic Article	Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX.
Academic Article	Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression.
Academic Article	Defining and Managing High-Risk Multiple Myeloma: Current Concepts.
Academic Article	Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life.
Academic Article	Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR.
Academic Article	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
Academic Article	Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
Academic Article	Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report.
Academic Article	Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
Academic Article	CAR T-cell therapy for multiple myeloma: state of the art and prospects.
Academic Article	Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy.
Academic Article	Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
Academic Article	The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.
Academic Article	Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
Academic Article	Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma.
Academic Article	Teclistamab, a B-cell maturation antigen???CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Academic Article	Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma.
Academic Article	Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis.
Academic Article	A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients.
Academic Article	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage.
Concept	Cancer Survivors
Concept	Tumor Microenvironment
Concept	Neoplasm Grading
Academic Article	Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
Academic Article	Current approaches to management of newly diagnosed multiple myeloma.
Academic Article	Extramedullary disease in multiple myeloma: a systematic literature review.
Academic Article	ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma.
Academic Article	Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
Academic Article	BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy.
Academic Article	Nutrition perceptions, needs and practices among patients with plasma cell disorders.
Academic Article	Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies.
Academic Article	Perspectives on the Risk-Stratified Treatment of Multiple Myeloma.
Academic Article	Teclistamab in Relapsed or Refractory Multiple Myeloma.
Academic Article	Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma.
Academic Article	A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy.
Academic Article	Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.
Academic Article	Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study.
Academic Article	Extreme body mass index and survival in newly diagnosed multiple myeloma patients.
Academic Article	Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets.
Academic Article	GPRC5D-Targeted CAR T Cells for Myeloma.
Academic Article	Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy.
Academic Article	A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma.
Academic Article	Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis.
Academic Article	The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific Antibodies.
Academic Article	Global disparities in patients with multiple myeloma: a rapid evidence assessment.
Academic Article	Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma.
Academic Article	Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma.
Academic Article	An Embarrassment of Riches: Three FDA-Approved Bispecific Antibodies for Relapsed Refractory Multiple Myeloma.
Academic Article	Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens.
Academic Article	Gene interaction network analysis in multiple myeloma detects complex immune dysregulation associated with shorter survival.
Academic Article	Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX.
Academic Article	Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study.
Academic Article	Addressing the disparities: the approach to the African American patient with multiple myeloma.
Academic Article	Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
Academic Article	Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma.
Academic Article	Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma.
Academic Article	Comparison of infectious complications with BCMA-directed therapies in multiple myeloma.
Academic Article	Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma.
Academic Article	The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma.
Academic Article	Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.
Academic Article	Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse.
Academic Article	Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4.
Academic Article	Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma.
Academic Article	Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study.
Academic Article	MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma.
Academic Article	Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignancies.
Academic Article	Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study.
Academic Article	CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53.
Academic Article	High WEE1 expression is independently linked to poor survival in multiple myeloma.

Search Criteria

Neoplasms